On Friday, July 31, AbbVie ABBV will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Earnings and Revenue
Analysts covering AbbVie modeled for quarterly EPS of $2.19 on revenue of $10.08 billion. AbbVie reported a per-share profit of $2.260 when it published results during the same quarter last year. Sales in that period totaled $8.26 billion. If the company were to match the consensus estimate, earnings would be down 3.1%. Revenue would be up 21.01% from the same quarter last year. AbbVie's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | 2.25 | 2.19 | 2.30 | 2.20 |
| EPS Actual | 2.42 | 2.21 | 2.33 | 2.26 |
| Revenue Estimate | 8.33 B | 8.70 B | 8.38 B | 8.10 B |
| Revenue Actual | 8.62 B | 8.70 B | 8.48 B | 8.26 B |
Stock Performance
Shares of AbbVie were trading at $97.04 as of July 30. Over the last 52-week period, shares are up 46.93%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. AbbVie is scheduled to hold the call at 09:00:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/u7bci37u
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
